Breast cancer awareness shouldn’t be limited to October.
Raise your #breastcancerawareness
Genomics is more than family history.
In late 2024, Rhythm Biosciences (ASX:RHY) completed an asset acquisition agreement for the Genetype business assets with business integration currently underway.
geneType continues to offer integrated risk testing for a range of serious conditions.
Disease prediction can allow for personalised preventive health plans to manage risk. Early detection can save lives.
Our Suite of Disease Risk Assessments
Get a further understanding of disease risk.
GeneType Multi-Risk Test
Order the full suite of diseases, or customize based on individual needs.
Take the first step towards personalised, preventative healthcare
Click on a test to learn more
 Breast Cancer
GeneType provides lifetime and 5-year risk scores for breast cancer
Colorectal Cancer
GeneType provides lifetime and 10-year risk scores for colorectal cancer
Ovarian Cancer
GeneType provides lifetime and 10-year risk scores for ovarian cancer
Prostate Cancer
GeneType provides lifetime and 5-year risk scores for prostate cancer
Coronary Artery Disease
GeneType provides a 10-year risk score for coronary artery disease
Type 2 Diabetes
GeneType provides an 8-year risk score for type 2 diabetes
 Multi-Risk Suite
Combine and customize the risk panel into a single test
Pancreatic Cancer
GeneType provides lifetime and 10-year risk scores for pancreatic cancer
Melanoma
GeneType provides lifetime and 10-year risk scores for melanoma
Atrial Fibrillation
GeneType provides a 10-year risk score for atrial fibrillation
We support the advancement of personalised, preventative healthcare.
The geneType test series outperform traditional risk models.
Let us help you integrate clinical, familial and genetic risk factors to provide a more comprehensive risk profile.
Accredited For Compliance With NPAAC Standards And ISO 15189
CLIA Number 99D2023356
Detecting cancer earlier and maintaining wellness
 The power of the combination of the Rhythm and Genetype capabilities and portfolio has the potential to dramatically improve early detection rates by providing an accessible, affordable, and accurate alternative that could save lives.
